Theranexus
Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Manufacturing
Description
THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-05-23 08:00 |
THERANEXUS PRÉSENTERA DE NOUVELLES DONNÉES SUR LES INTERACTIONS NEUROGLIALES LO…
|
French | 292.7 KB | ||
| 2019-04-24 07:30 |
THERANEXUS ANNOUNCES ISSUANCE OF CHINESE PATENT COVERING ITS DRUG CANDIDATE THN…
|
English | 380.2 KB | ||
| 2019-04-24 07:30 |
THERANEXUS ANNONCE LA DÉLIVRANCE EN CHINE D'UN BREVET COUVRANT SON CANDIDAT MÉD…
|
French | 295.3 KB | ||
| 2019-04-17 07:30 |
THERANEXUS ANNONCE SES RÉSULTATS ANNUELS 2018 ET PRÉSENTE UN POINT D'ACTUALITÉ …
|
French | 316.6 KB | ||
| 2019-04-17 07:30 |
THERANEXUS PROVIDES 2018 FULL-YEAR RESULTS AND UPDATE ON ACTIVITIES
|
English | 415.8 KB | ||
| 2019-04-09 07:30 |
THERANEXUS ANNOUNCES RESEARCH COLLABORATION WITH IRISA* USING ARTIFICIAL INTELL…
|
English | 379.1 KB | ||
| 2019-04-09 07:30 |
THERANEXUS ANNONCE UNE COLLABORATION DE RECHERCHE AVEC L'IRISA* UTILISANT DES T…
|
French | 291.1 KB | ||
| 2019-03-26 07:30 |
THERANEXUS PRÉSENTERA DE NOUVELLES DONNÉES SCIENTIFIQUES SUR SON CANDIDAT MÉDIC…
|
French | 387.7 KB | ||
| 2019-03-26 07:30 |
THERANEXUS TO PRESENT NEW SCIENTIFIC DATA ON DRUG CANDIDATE THN201 AT AD/PD 201…
|
English | 376.7 KB | ||
| 2019-02-27 18:15 |
THERANEXUS ANNOUNCES PRELIMINARY RESULTS OF PHASE II TRIAL OF THN102 ON NARCOLE…
|
English | 381.2 KB | ||
| 2019-02-27 18:15 |
THERANEXUS ANNONCE LES RÉSULTATS PRÉLIMINAIRES DE L'ÉTUDE DE PHASE 2 DU THN102 …
|
French | 281.1 KB | ||
| 2019-02-13 18:00 |
THERANEXUS REPORTS CASH POSITION AS OF 31 DECEMBER 2018 AND PROVIDES UPDATE ON …
|
English | 394.6 KB | ||
| 2019-02-13 18:00 |
THERANEXUS PUBLIE SA TRÉSORERIE AU 31 DÉCEMBRE 2018 ET PRÉSENTE UN POINT SUR L'…
|
French | 295.4 KB | ||
| 2019-01-29 18:00 |
THERANEXUS set to receive EUR 6.2 million in funding from the French Investment…
|
English | 378.0 KB | ||
| 2019-01-29 18:00 |
THERANEXUS bénéficie d'un financement de 6,2 millions d'euros du Programme d'in…
|
French | 367.5 KB |
Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Theranexus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Theranexus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
